Richard Law CFA
Stock Analyst at Goldman Sachs
(3.70)
# 2,075
Out of 4,600 analysts
125
Total ratings
50%
Success rate
9.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLN Silence Therapeutics | Maintained: Sell | $4 | $10.68 | -62.55% | 4 | Jul 27, 2026 | |
| CLDX Celldex Therapeutics | Reiterated: Hold | $38 → $34 | $37.69 | -9.79% | 6 | Jul 22, 2026 | |
| COAG Hemab Therapeutics Holdings | Maintained: Buy | $36 → $46 | $45.00 | +2.22% | 2 | Jul 13, 2026 | |
| VRDN Viridian Therapeutics | Rated: Buy | $35 → $39 | $19.31 | +101.97% | 10 | Jun 29, 2026 | |
| PTGX Protagonist Therapeutics | Maintained: Hold | $110 | $132.28 | -16.84% | 6 | Jun 10, 2026 | |
| MLYS Mineralys Therapeutics | Maintained: Buy | $42 | $25.78 | +62.92% | 12 | Jun 3, 2026 | |
| BCAX Bicara Therapeutics | Maintained: Hold | $18 | $25.74 | -30.07% | 4 | Jun 1, 2026 | |
| OLMA Olema Pharmaceuticals | Maintained: Buy | $27 → $23 | $11.28 | +103.90% | 9 | May 12, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintained: Sell | $11 → $12 | $17.40 | -31.03% | 8 | May 11, 2026 | |
| RCUS Arcus Biosciences | Maintained: Buy | $30 → $34 | $27.62 | +23.10% | 3 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $3 | $3.41 | -12.02% | 7 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $67 | $83.76 | -20.01% | 5 | Mar 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $29 → $33 | $25.94 | +27.22% | 3 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $30 → $33 | $32.61 | n/a | 2 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $36 → $31 | $15.17 | n/a | 6 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $47 | $25.91 | n/a | 4 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $62 → $63 | $49.57 | n/a | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $36 → $37 | $100.31 | n/a | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $76 | $10.77 | n/a | 7 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 | $15.38 | n/a | 3 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $15 → $14 | $2.65 | n/a | 3 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $61 | $8.06 | n/a | 5 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $10 | $3.50 | n/a | 2 | Feb 24, 2023 |
Silence Therapeutics
Jul 27, 2026
Maintained: Sell
Price Target: $4
Current: $10.68
Upside: -62.55%
Celldex Therapeutics
Jul 22, 2026
Reiterated: Hold
Price Target: $38 → $34
Current: $37.69
Upside: -9.79%
Hemab Therapeutics Holdings
Jul 13, 2026
Maintained: Buy
Price Target: $36 → $46
Current: $45.00
Upside: +2.22%
Viridian Therapeutics
Jun 29, 2026
Rated: Buy
Price Target: $35 → $39
Current: $19.31
Upside: +101.97%
Protagonist Therapeutics
Jun 10, 2026
Maintained: Hold
Price Target: $110
Current: $132.28
Upside: -16.84%
Mineralys Therapeutics
Jun 3, 2026
Maintained: Buy
Price Target: $42
Current: $25.78
Upside: +62.92%
Bicara Therapeutics
Jun 1, 2026
Maintained: Hold
Price Target: $18
Current: $25.74
Upside: -30.07%
Olema Pharmaceuticals
May 12, 2026
Maintained: Buy
Price Target: $27 → $23
Current: $11.28
Upside: +103.90%
MoonLake Immunotherapeutics
May 11, 2026
Maintained: Sell
Price Target: $11 → $12
Current: $17.40
Upside: -31.03%
Arcus Biosciences
May 7, 2026
Maintained: Buy
Price Target: $30 → $34
Current: $27.62
Upside: +23.10%
Mar 27, 2026
Maintained: Sell
Price Target: $3
Current: $3.41
Upside: -12.02%
Mar 1, 2026
Maintained: Buy
Price Target: $67
Current: $83.76
Upside: -20.01%
Feb 27, 2026
Maintained: Hold
Price Target: $29 → $33
Current: $25.94
Upside: +27.22%
Jul 24, 2025
Maintained: Hold
Price Target: $30 → $33
Current: $32.61
Upside: n/a
Aug 15, 2023
Maintained: Hold
Price Target: $36 → $31
Current: $15.17
Upside: n/a
Aug 9, 2023
Maintained: Hold
Price Target: $47
Current: $25.91
Upside: n/a
Aug 8, 2023
Maintained: Hold
Price Target: $62 → $63
Current: $49.57
Upside: n/a
Aug 4, 2023
Maintained: Hold
Price Target: $36 → $37
Current: $100.31
Upside: n/a
Jun 13, 2023
Reiterated: Buy
Price Target: $76
Current: $10.77
Upside: n/a
May 12, 2023
Reiterated: Hold
Price Target: $11
Current: $15.38
Upside: n/a
May 5, 2023
Maintained: Hold
Price Target: $15 → $14
Current: $2.65
Upside: n/a
May 5, 2023
Maintained: Buy
Price Target: $61
Current: $8.06
Upside: n/a
Feb 24, 2023
Upgraded: Hold
Price Target: $10
Current: $3.50
Upside: n/a